NCT05765877View on ClinicalTrials.gov

Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2029

Conditions
Non-Small Cell Lung Cancer(NSCLC)
Interventions
DRUG

WX-0593 Tablets

60 mg of WX-0593 tablets, once daily for 7 days, followed by 180 mg of WX-0593 tablets, once daily in a 28-days cycle.

Trial Locations (1)

250117

RECRUITING

Shandong Cancer Hospital and Institute, Jinan

All Listed Sponsors
lead

Pingping Song

OTHER